Medical consumables national brand opportunities coming?
The company's main business is to promote the use of medical supplies, and to promote the use of medical supplies. The Measures require that when medical institutions purchase medical equipment, they should fully consider the cost of supporting the use of medical consumables, and take it as an important reference factor for the purchase of medical equipment.
A domestic medical device company executives told reporters that this is both an opportunity and a challenge for domestic medical device companies. In the case of medical institutions to reduce procurement costs, the original high price of imported consumables is expected to be replaced by low-priced, good quality domestic consumables, which is an opportunity. However, the challenges faced by the industry as a whole should not be underestimated. Combined with the previous policies such as the sunshine procurement of consumables, the overall medical device industry is under pressure to reduce prices, and enterprises need to change the original distribution chain and sales model.
2026-07-22
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
Synthomer Sells Its Last Upstream Chemical Business
-
Wuxi Yinda Nylon Acquires German Century-Old Chemical Giant Perlon
-
Aldi Expands Its Ingredient Ban
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
EFSA Evaluates Extended Use of Pasteurised Akkermansia muciniphila as a Novel Food
-
Supply Contraction Meets Weak Consumption—PCs Consolidate in Early May
-
Microcrystalline Cellulose: Applications in Pharmaceuticals
-
Maintenance Concentration Leads to Cost Decline; April PP Market Experiences Volatile Performance
-
Premium Global Chemical Sourcing Requests (07-10May, 2026)
-
This week's anhydrous hydrogen fluoride market remains stable (10.13-10.16)